machineMD announced a strategic investment from Topcon Healthcare. This partnership aligns with Topcon Healthcare’s mission to deliver Healthcare from the Eye, enhancing access to high-quality care while optimizing health care costs, the companies said in a joint press release.
Topcon Healthcare has joined machineMD’s pre-Series A funding round as the lead investor, underscoring a shared commitment to advancing neurodiagnostics through ocular data. According to the press release, this collaboration will integrate machineMD’s objective functional neurodiagnostics with Topcon’s Harmony digital health information platform, fostering earlier detection of neurological diseases within a connected care ecosystem,
Founded with a vision to enable faster, more accurate, and earlier diagnoses of neurological disorders, machineMD said it is pioneering oculometric analysis to assess brain function with precision. By leveraging neurodiagnostic expertise, the company is developing solutions that support individuals affected by conditions such as multiple sclerosis and Parkinson’s disease.
“Topcon Healthcare and machineMD share a bold ambition to shape the future of neurodiagnostics—making it more accessible, scalable, and data-driven,” said Dominic Senn, CEO and co-founder of machineMD, in the press release. “With the backing of forward-thinking partners like Topcon Healthcare and our expanding network of clinical experts, we are accelerating our journey to establishing neurodiagnostics as the standard of care—ultimately improving millions of lives.”
Topcon Healthcare’s initiative, Healthcare from the Eye, utilizes ocular data to identify ocular, systemic, or neurological disease in a coordinated care system that includes eyecare providers, primary care providers, and specialty care providers using secure and responsible technology. Through this partnership, machineMD’s neurodiagnostic capabilities will be integrated into Topcon Healthcare’s multimodal retinal imaging technologies, which according to the press release, will unlock faster, cost-effective pathways for neurological disease detection and management.
According to the press release, machineMD’s flagship product, neos, leverages VR technology and gamified visual stimuli to capture precise oculomotor and pupillometric data. Already in clinical use across Switzerland and the United States, neos is streamlining workflows, paving the way for scalable and reimbursable neurodiagnostics
“Our investment in machineMD reflects our commitment to expanding ocular-based diagnostics into the realm of neurological diseases," said Ali Tafreshi, CEO and president of Topcon Healthcare, in the press release. "machineMD’s expertise and cutting-edge technology will enable more precise and earlier diagnoses, ultimately improving patient outcomes."
By combining machineMD’s neurodiagnostic functional biomarkers with Topcon Healthcare’s multimodal retinal imaging-based biomarkers, the partnership will enhance clinical decision-making and patient management. Delivering these innovations through the Harmony cloud-based platform will create a seamless digital ecosystem for ocular and neurological diagnostics, empowering health care professionals with integrated data-driven insights, the press release stated.